Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04367831 · ClinicalTrials.gov registry record · Phase 4
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
A Phase 4 study of COVID-19 and Venous Thromboses, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT04367831 is a Phase 4 study of COVID-19 and Venous Thromboses that has completed, run by Columbia University. The registered enrollment target is 94 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04367831, a Phase 4 study of COVID-19 and Venous Thromboses, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care but determining the dose of anticoagulation is based on physician preference. The investigators are conducting this study (a randomized trial with adaptive design employing cluster randomization) with the support of all of the ICUs to collect data in order to determine what should be the standard of care in terms of anticoagulation in these critically ill patients. The patients care will not be altered other than the choice of anticoagulation (both approved and used throughout the hospital as standard of care) based on the ICU bed they are assigned. Patient data will be collected until discharge.
Conditions Studied
Interventions
- DRUG Enoxaparin Prophylactic Dose
- DRUG Heparin Infusion
- DRUG Heparin SC
- DRUG Enoxaparin/Lovenox Intermediate Dose
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2020-05-02 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04367831
The ClinicalTrials.gov registry entry for NCT04367831 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Enoxaparin Prophylactic Dose is the first listed.
NCT04367831 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04367831 about?
NCT04367831 is a clinical study titled "Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19". This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care...
What is the current status of trial NCT04367831?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 94 participants. The study started on 2020-05-02. Estimated completion is 2021-05-12.
What conditions does trial NCT04367831 study?
This clinical trial studies the following conditions: COVID-19, Venous Thromboses, Arterial Thrombosis.
What interventions are being tested in trial NCT04367831?
The interventions under investigation include: Enoxaparin Prophylactic Dose (DRUG), Heparin Infusion (DRUG), Heparin SC (DRUG), Enoxaparin/Lovenox Intermediate Dose (DRUG).
Who is sponsoring clinical trial NCT04367831?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04367831 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.